RJA
LGND icon

Raymond James & Associates’s Ligand Pharmaceuticals LGND Stock Holding History

Raymond James & Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$213K Buy
+2,127
New +$214K ﹤0.01% 3612
2023
Q2 		– Sell
-3,334
Closed -$245K – 3912
2023
Q1 		$245K Sell
3,334
-10
-0.3% -$711 ﹤0.01% 3379
2022
Q4 		$223K Sell
3,344
-2,053
-38% -$133K ﹤0.01% 3389
2022
Q3 		$290K Sell
5,397
-34
-0.6% -$2K ﹤0.01% 3203
2022
Q2 		$302K Sell
5,431
-176
-3% -$9.99K ﹤0.01% 3231
2022
Q1 		$393K Hold
5,607
– – ﹤0.01% 3225
2021
Q4 		$540K Hold
5,607
– – ﹤0.01% 3023
2021
Q3 		$487K Sell
5,607
-266
-5% -$20.6K ﹤0.01% 3082
2021
Q2 		$481K Sell
5,873
-21,758
-79% -$1.81M ﹤0.01% 3101
2021
Q1 		$2.63M Sell
27,631
-14,345
-34% -$1.36M ﹤0.01% 1832
2020
Q4 		$2.6M Sell
41,976
-895
-2% -$51K ﹤0.01% 1739
2020
Q3 		$2.55M Buy
42,871
+14,063
+49% +$960K ﹤0.01% 1606
2020
Q2 		$2.01M Buy
28,808
+13,855
+93% +$878K ﹤0.01% 1725
2020
Q1 		$678K Sell
14,953
-1,601
-10% -$90.7K ﹤0.01% 2221
2019
Q4 		$1.08M Sell
16,554
-2,235
-12% -$149K ﹤0.01% 2229
2019
Q3 		$1.17M Sell
18,789
-1,047
-5% -$65.7K ﹤0.01% 2107
2019
Q2 		$1.41M Buy
19,836
+897
+5% +$66.1K ﹤0.01% 2012
2019
Q1 		$1.49M Sell
18,939
-3,216
-15% -$244K ﹤0.01% 1962
2018
Q4 		$1.88M Sell
22,155
-5,468
-20% -$583K ﹤0.01% 1700
2018
Q3 		$4.73M Buy
27,623
+1,582
+6% +$239K 0.01% 1239
2018
Q2 		$3.37M Buy
26,041
+508
+2% +$56.7K 0.01% 1423
2018
Q1 		$2.63M Buy
25,533
+10,351
+68% +$1.02M ﹤0.01% 1530
2017
Q4 		$1.3M Buy
15,182
+1,153
+8% +$99.9K ﹤0.01% 1977
2017
Q3 		$1.19M Buy
14,029
+141
+1% +$11.2K ﹤0.01% 1990
2017
Q2 		$1.05M Buy
13,888
+357
+3% +$25K ﹤0.01% 1994
2017
Q1 		$893K Buy
13,531
+617
+5% +$40.6K ﹤0.01% 2038
2016
Q4 		$819K Buy
12,914
+2,818
+28% +$178K ﹤0.01% 2050
2016
Q3 		$643K Sell
10,096
-7,306
-42% -$536K ﹤0.01% 2121
2016
Q2 		$1.29M Buy
17,402
+8,957
+106% +$665K ﹤0.01% 1591
2016
Q1 		$564K Buy
+8,445
New +$513K ﹤0.01% 1983

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Raymond James & Associates's LGND Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Ligand Pharmaceuticals (LGND) in Q3 2024: 2,127 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #3612 among its holdings. This is a return to the name: Raymond James & Associates previously reported a position in LGND as recently as Q1 2023.

Raymond James & Associates first reported a position in LGND in Q1 2016 and has held it in 30 quarters since. The position peaked at $4.73M in Q3 2018. 243 funds tracked by Wall St. Rank hold LGND as of Q3 2024.

  • Raymond James & Associates held 2,127 shares of Ligand Pharmaceuticals worth $213K as of Q3 2024.
  • Ligand Pharmaceuticals was a new Raymond James & Associates position in Q3 2024.
  • Ligand Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3612 holding.
  • Raymond James & Associates first reported a position in Ligand Pharmaceuticals in Q1 2016 and has held it in 30 quarters since.
  • Raymond James & Associates's Ligand Pharmaceuticals position peaked at $4.73M in Q3 2018.
  • 243 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.